Skip to content Skip to footer
Subscribe Now
Top biosimilar news of the Apr 2025
INSIGHTS+

Key Biosimilars Events of April 2025  

Shots:        Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency         Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients         Henlius Collaborates with Sandoz for the Commercialization of HLX13. Our team at PharmaShots…
May 6, 2025

Read more

THOUGHTSPOT

How Healthcare Teaching Shapes Future Medical Practices

Teaching in healthcare involves guiding future professionals in how they think through problems, interact with colleagues, and make informed decisions during clinical work. If you’re involved in clinical training, your ability to teach effectively can influence how future clinicians treat patients and how confidently they move through high-pressure environments. Courses focused on teaching methodologies help…
May 6, 2025

Read more

Hlth
EVENTS

2025 | HLTH Europe: 16-19 June | Amsterdam

HLTH Europe is the continent’s #1 healthcare innovation event. Following an enormously successful first event in 2024 and the exponential growth of HLTH in the US, this landmark event is where global expertise meets local insight to address Europe's unique healthcare challenges and opportunities. Don’t miss out on this opportunity to connect with like-minded individuals…
May 6, 2025

Read more

Takeda at AASLD 2024: Chinwe Ukomadu in a Riveting Dialogue Exchange with PharmaShots
VIEWPOINTS

Takeda at AASLD 2024: Chinwe Ukomadu in a Riveting Dialogue Exchange with PharmaShots

Shots:   AATD-associated liver disease is a progressive genetic disorder with no approved therapy, and liver transplantation remains the only option for patients with end-stage disease.  Fazirsiran is an investigational RNAi therapy designed to treat AATD-associated liver disease by lowering the production of Z-AAT.  PharmaShots welcomes Dr. Chinwe Ukomadu, Head of the Gastrointestinal and Inflammation Therapeutic…
May 5, 2025

Read more

Spotlight_Barbara Albientz
EVENTS

Reuters Pharma 2025: Post-Conference Talks Featuring Barbara Albientz

Barbara Albientz, Chief Commercialization Officer, Helvion Pharmaceuticals, joins PharmaShots’ Managing Editor Himanshu Sehgal for a riveting dialogue exchange. Barbara shares her experience from the recently held Reuters Events Pharma 2025, where she joined as an affirmative team member for the debate Reality Check: Is Omnichannel Actually Working? Barbara believes AI will be crucial in segmenting…
May 1, 2025

Read more

Insight+_Ridhi Rastogi
INSIGHTS+

New Drug Designations – March 2025 

Shots:      PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA    The March 2025 report covers designations granted to 37 drugs and 3 medical devices, spanning 11 small molecules, 10 biologics, 10 cell and gene therapies & 3 medical devices among…
April 29, 2025

Read more

Spotlight_Jayasree Iyer
EVENTS

Reuters Pharma 2025: Post Conference Talks Featuring Jayasree K. Iyer 

Jayasree K. Iyer, CEO of Access to Medicine Foundation, moderated a panel discussion that featured leaders from the 2024 Access to Medicine Index. Jayasree highlighted how biopharma companies foster accessibility to essential medicines in low- and middle-income countries through global partnerships, innovation, and sustainable models. Jayasree talks about the future of Health Equity amidst the…
April 29, 2025

Read more

Viewpoints_Jesse Mendelsohn
VIEWPOINTS

Predicting 2025 Trends: Jesse Mendelsohn from Model N in an Illuminating Discussion with PharmaShots

Shots:  Several undulating factors coalesce to inadvertently shape the biopharma industry  Prominent challenges include mounting pressure on Pharmacy Benefit Managers from independent pharmacies and drug manufacturers, a growing shortage of GLP-1 drugs, and the addition of 15 more drugs to the Inflation Reduction Act’s price negotiation list.  Jesse Mendelsohn, SVP at Model N, emphasizes the…
April 28, 2025

Read more

Load more